Help paying · Medicare negotiated price · pharmacy cost · cycle 2027
Ozempic (semaglutide): where help paying exists, what Medicare negotiated and what pharmacies pay
4 assistance programs list semaglutide, each with its income ceiling and when we read it. Medicare's negotiated price for a 30-day supply is $274 on January 1, 2027. 12 non-manufacturing label changes are dated in the last 12 months in the FDA's file. The FDA's enforcement reports name this drug's packages in 4 recall entries. ClinicalTrials.gov lists 154 recruiting trials that name semaglutide.
Every package we can price
Per-unit prices (per each unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 00169-1704-30 | OZEMPIC 4MG BOTTLE | EA | n/a | $9.23 | $33.19 | - |
| 00169-1709-30 | OZEMPIC 9MG BOTTLE | EA | n/a | $9.23 | $33.19 | - |
| 00169-1715-30 | OZEMPIC 1.5MG BOTTLE | EA | n/a | $9.23 | $33.15 | - |
| 00169-4130-01 | OZEMPIC 1MG 1X3ML INNER | ML | n/a | $92.26 | $332 | - |
| 00169-4130-13 | OZEMPIC 1MG 1X3ML | ML | n/a | $92.26 | $332 | - |
| 00169-4132-11 | OZEMPIC 0.25MG/0.5MG, 2MG/1.5ML INNER | n/a | n/a | $178 | n/a | no NADAC price |
| 00169-4132-12 | OZEMPIC 0.25MG/0.5MG, 2MG/1.5ML | n/a | n/a | $178 | n/a | no NADAC price |
| 00169-4136-02 | OZEMPIC 1MG, 2MG/1.5ML | n/a | n/a | $92.26 | n/a | no NADAC price |
| 00169-4136-11 | OZEMPIC 1MG, 2MG/1.5ML INNER | n/a | n/a | $92.26 | n/a | no NADAC price |
| 00169-4181-03 | OZEMPIC 0.25MG/0.5MG 1X3ML INNER | ML | n/a | $92.26 | $332 | - |
| 00169-4181-13 | OZEMPIC 0.25MG/0.5MG 1X3ML | ML | n/a | $92.26 | $332 | - |
| 00169-4303-01 | RYBELSUS 3MG 3X10 TABLETS INNER | n/a | n/a | $9.23 | n/a | no NADAC price |
| 00169-4303-13 | RYBELSUS 3MG 3X10 TABLETS | n/a | n/a | $9.23 | n/a | no NADAC price |
| 00169-4303-30 | RYBELSUS 3MG BOTTLE 30 TAB | EA | n/a | $9.23 | $33.19 | - |
| 00169-4307-01 | RYBELSUS 7MG 3X10 TABLETS INNER | n/a | n/a | $9.23 | n/a | no NADAC price |
| 00169-4307-13 | RYBELSUS 7MG 3X10 TABLETS | n/a | n/a | $9.23 | n/a | no NADAC price |
| 00169-4307-30 | RYBELSUS 7MG BOTTLE 30 TAB | EA | n/a | $9.23 | $33.19 | - |
| 00169-4314-01 | RYBELSUS 14MG 3X10 TABLETS INNER | n/a | n/a | $9.23 | n/a | no NADAC price |
| 00169-4314-13 | RYBELSUS 14MG 3X10 TABLETS | n/a | n/a | $9.23 | n/a | no NADAC price |
| 00169-4314-30 | RYBELSUS 14MG BOTTLE 30 TAB | EA | n/a | $9.23 | $33.19 | - |
| 00169-4404-31 | WEGOVY 4MG BOTTLE | EA | n/a | $12.85 | $43.49 | - |
| 00169-4409-31 | WEGOVY 9MG BOTTLE | EA | n/a | $12.85 | $43.48 | - |
| 00169-4415-31 | WEGOVY 1.5MG BOTTLE | EA | n/a | $12.85 | $43.53 | - |
| 00169-4425-31 | WEGOVY 25MG BOTTLE | EA | n/a | $12.85 | $43.46 | - |
| 00169-4501-01 | WEGOVY 1MG .5ML INNER | n/a | n/a | $193 | n/a | no NADAC price |
| 00169-4501-14 | WEGOVY 1MG 4X.5ML | ML | n/a | $193 | $653 | - |
| 00169-4505-01 | WEGOVY 0.5MG .5ML INNER | n/a | n/a | $193 | n/a | no NADAC price |
| 00169-4505-14 | WEGOVY 0.5MG 4X.5ML | ML | n/a | $193 | $653 | - |
| 00169-4517-01 | WEGOVY 1.7MG .75ML INNER | n/a | n/a | $129 | n/a | no NADAC price |
| 00169-4517-14 | WEGOVY 1.7MG 4X.75ML | ML | n/a | $129 | $436 | - |
| 00169-4524-01 | WEGOVY 2.4MG .75ML INNER | n/a | n/a | $129 | n/a | no NADAC price |
| 00169-4524-14 | WEGOVY 2.4MG 4X.75ML | ML | n/a | $129 | $436 | - |
| 00169-4525-01 | WEGOVY 0.25MG .5ML INNER | n/a | n/a | $193 | n/a | no NADAC price |
| 00169-4525-14 | WEGOVY 0.25MG 4X.5ML | ML | n/a | $193 | $653 | - |
| 00169-4572-01 | WEGOVY 7.2MG 4X.75ML INNER | n/a | n/a | $129 | n/a | no NADAC price |
| 00169-4572-14 | WEGOVY 7.2MG 4X.75ML | ML | n/a | $129 | $435 | - |
| 00169-4772-11 | OZEMPIC 2MG 1X3ML INNER | ML | n/a | $92.22 | $332 | - |
| 00169-4772-12 | OZEMPIC 2MG 1X3ML | ML | n/a | $92.22 | $332 | - |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA209637 | Ozempic 0.25mg/0.5mg 1x3ml, Ozempic 1mg 1x3ml, Ozempic 2mg 1x3ml | February 17, 2041 | January 28, 2028 | February 17, 2041 | patent 11318191; 93 dated entries listed |
| NDA213051 | Ozempic 1.5mg Bottle, Ozempic 4mg Bottle, Ozempic 9mg Bottle, Rybelsus | February 1, 2039 | October 17, 2028 | February 1, 2039 | patent 11833248; 79 dated entries listed |
| NDA215256 | Wegovy 0.25mg 4x.5ml, Wegovy 0.5mg 4x.5ml, Wegovy 1.7mg 4x.75ml, Wegovy 1mg 4x.5ml and 2 more | February 17, 2041 | March 19, 2029 | February 17, 2041 | patent 11318191; 119 dated entries listed |
| NDA218316 | Wegovy 1.5mg Bottle, Wegovy 25mg Bottle, Wegovy 4mg Bottle, Wegovy 9mg Bottle | February 1, 2039 | December 22, 2028 | February 1, 2039 | patent 11833248; 42 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Ozempic of $12.97 billion in 2024, across 10,417,182 claims and 1,952,637 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $12.97 billion | 10,417,182 | 1,952,637 | $1,245 |
| 2023 | $9.19 billion | 6,927,972 | 1,464,468 | $1,327 |
| 2022 | $4.63 billion | 3,410,839 | 780,253 | $1,357 |
| 2021 | $2.62 billion | 2,016,177 | 458,643 | $1,300 |
| 2020 | $1.46 billion | 1,204,138 | 269,663 | $1,209 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 10 states with the largest reimbursement are shown of 31 with data. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| NC | 203,087 | $270,679,993 | All record types |
| SC | 9,814 | $12,534,738 | Fee-for-service only |
| OH | 7,641 | $9,969,301 | Fee-for-service only |
| CO | 6,734 | $8,048,009 | Fee-for-service only |
| TX | 4,638 | $5,363,868 | Fee-for-service only |
| NJ | 3,829 | $5,071,837 | Fee-for-service only |
| IN | 3,142 | $4,124,973 | Fee-for-service only |
| LA | 2,074 | $2,656,842 | Fee-for-service only |
| OR | 1,460 | $1,847,381 | Fee-for-service only |
| GA | 1,189 | $1,502,658 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (60 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 364 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
Offers the program pages state
- Manufacturer self-pay price
The NovoCare Ozempic savings-offer page states a self-pay price: $199 per month for the first 2 monthly fills of the 0.25 mg and 0.5 mg pen through December 31, 2026, then $349 per month for 0.25, 0.5 or 1 mg and $499 per month for 2 mg; its pricing table also shows self pay starting at $149 per month for a 1.5 mg dose. Marked a limited time offer; pricing to be updated after December 31, 2026.
Limited time: Pricing to be updated after December 31, 2026.
Read November 7, 2026; quote matched against the saved page text. - Manufacturer savings card
The NovoCare Ozempic savings-offer page states: pay as little as $25 per month for up to a 3-month prescription with commercial insurance, subject to a maximum savings of $100 per month; government beneficiaries are excluded.
Read November 7, 2026; quote matched against the saved page text.
Programs in our finder that list semaglutide. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- Novo Nordisk Patient Assistance Program (Ozempic) manufacturer
Ozempic is available to uninsured patients only; Novo Nordisk states no income figure (its pages read 29 October 2026), so call 1-866-310-7549 to ask
Limit read October 29, 2026.Status. Novo Nordisk states that Medicare beneficiaries with prescription drug coverage will no longer be eligible to receive Ozempic through its Patient Assistance Program, and that some medicines will no longer be part of the program for 2026 (the page points to a separate list of the medicines that remain covered). (read November 7, 2026)
- Ozempic Savings Card (Novo Nordisk) manufacturer
No income limit in our data
Figure not yet re-read on the program's own page. - HealthWell Foundation nonprofit
Up to 300% to 500% FPL depending on the disease fund; many funds close to new patients
Ceiling matched against the program's page text, November 6, 2026.Status. The HealthWell Foundation homepage lists disease funds as Open or Closed when read. Closed funds include Type 2 Diabetes, Migraine and Multiple Sclerosis - Medicare Access; open funds include Multiple Myeloma - Medicare Access, which the page says offers up to $8,000 in prescription drug copayment or Medicare Part B premium assistance. The page carries no fund-level date; the status is as of the read. (read November 7, 2026)
- Good Days (formerly Chronic Disease Fund) nonprofit
Income at or below 500% of the poverty level
Figure not yet re-read on the program's own page.
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
FDA actions on the applications behind Ozempic dated since November 11, 2025, leaving out manufacturing (CMC) changes. 12 changes in the window.
| Date | Class | Application | Submissions | FDA documents |
|---|---|---|---|---|
| August 27, 2026 | Labeling | NDA209637 | 44 | Label (PDF) posted August 28, 2026FDA letter posted August 28, 2026 |
| June 18, 2026 | Labeling | NDA218316 | 7 | Label (PDF) posted June 23, 2026 |
| June 1, 2026 | Labeling | NDA209637 | 38 | Label (PDF) posted June 10, 2026FDA letter posted June 2, 2026 |
| May 5, 2026 | Labeling | NDA218316 | 3 | Label (PDF) posted May 12, 2026 |
| March 19, 2026 | Efficacy | NDA215256 | 29 | Label (PDF) posted August 24, 2026FDA letter posted March 23, 2026 |
| March 19, 2026 | Labeling | NDA218316 | 5 | Label (PDF) posted March 24, 2026FDA letter posted March 23, 2026 |
| February 25, 2026 | Labeling | NDA215256 | 33 | Label (PDF) posted March 2, 2026FDA letter posted February 27, 2026 |
| February 25, 2026 | Labeling | NDA218316 | 4 | Label (PDF) posted March 2, 2026FDA letter posted February 27, 2026 |
| January 30, 2026 | Labeling | NDA213051 | 30 | Label (PDF) posted July 31, 2026FDA letter posted February 3, 2026 |
| January 29, 2026 | Labeling | NDA215256 | 30 | Label (PDF) posted January 29, 2026FDA letter posted January 30, 2026 |
| January 29, 2026 | Labeling | NDA218316 | 2 | Label (PDF) posted February 5, 2026FDA letter posted January 30, 2026 |
| November 21, 2025 | Efficacy | NDA215256 | 23 | Label (PDF) posted November 25, 2025FDA letter posted November 24, 2025 |
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Safety notices
FDA enforcement report entries that name a package of Ozempic by its NDC: 4 entries, newest first. FDA assigns each a class by health risk: Class I is the most serious and Class III the least. An entry records what the recalling firm reported and FDA classified; it is not advice about any package you hold.
| Reported | Class | Status | Recalling firm | Reason (shortened) | Packages named |
|---|---|---|---|---|---|
| January 7, 2026D-0244-2026 | Class II | Ongoing | Novo Nordisk Inc. | Presence of Particulate Matter: Hair was found in a prefilled syringe | 1 |
| January 7, 2026D-0245-2026 | Class II | Ongoing | Novo Nordisk Inc. | Presence of Particulate Matter: Hair was found in a prefilled syringe | 1 |
| May 7, 2025D-0393-2025 | Class II | Ongoing | Cardinal Health Inc. | Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated... | 1 |
| June 2, 2021D-0536-2021 | Class II | Terminated | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. | 12 |
Source: openFDA drug enforcement reports, file read November 7, 2026. openFDA data file. All recent recalls across these drugs: drug recalls feed.
Clinical trials recruiting
ClinicalTrials.gov lists 154 interventional trials that name semaglutide and are recruiting, and 88 more not yet recruiting. By phase: Phase 4: 37, Phase 3: 32, Phase 2: 29, Not applicable: 28, Phase 1: 15, PHASE2/PHASE3: 6, PHASE1/PHASE2: 5, Early phase 1: 2. The 10 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT07651319 | Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseAlzheimer Dementia (AD) | Phase 1 / Phase 2 | The Methodist Hospital Research Institute | November 6, 2026 | United States |
| NCT07866066 | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesDiabetes Mellitus, Type 2 | Phase 3 | Amgen | November 5, 2026 | United States, Canada |
| NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityObesity; Overweight and/or Obesity; Overweight | Phase 3 | Pfizer | November 5, 2026 | United States, Australia |
| NCT06897475 | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideType 2 Diabetes | Phase 2 | Eli Lilly and Company | November 4, 2026 | United States, Canada, Germany and 3 more |
| NCT07772960 | Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use OutcomesAlcohol Use Disorder (AUD); Obesity (BMI Equal to or >30) | Phase 1 | Yale University | November 4, 2026 | United States |
| NCT06975111 | Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthMenopause; Menopause Hot Flashes; Menopause Related Conditions | Phase 2 / Phase 3 | University of Colorado, Denver | November 4, 2026 | United States |
| NCT07840729 | Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese ParticipantsValid MeSH Conditiongs | Phase 1 | Shanghai JMT-Bio Inc. | November 2, 2026 | China |
| NCT07872904 | FutureShape FamilyObesity; Overweight | Phase 4 | Signe Torekov | October 29, 2026 | Denmark |
| NCT07900438 | A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in ChinaCardiovascular Risk; Chronic Kidney Disease | Phase 4 | Novo Nordisk A/S | October 28, 2026 | China |
| NCT07900074 | Mechanisms of Weight Loss: Tirzepatide vs SemaglutideObesity (Disorder) | Phase 4 | McMaster University | October 28, 2026 | Canada |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Ozempic?
The CMS file publishes $274 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
The two CMS files do not give a comparable per-unit price for this drug.
Is there help paying for Ozempic?
4 assistance programs list it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
When could a generic version of Ozempic arrive?
For Ozempic, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA209637, February 17, 2041; NDA213051, February 1, 2039; NDA215256, February 17, 2041; NDA218316, February 1, 2039. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Ozempic?
ClinicalTrials.gov lists 154 recruiting interventional trials that name semaglutide (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Ozempic?
CMS's Medicare Part D spending dataset reports gross spending on Ozempic of $12.97 billion in 2024, across 10,417,182 claims and 1,952,637 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/ozempic.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; openFDA drug enforcement reports; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.